Pacira (PCRX) Financing Deal Removes Overhang
Get Alerts PCRX Hot Sheet
Price: $29.22 +0.62%
Rating Summary:
16 Buy, 11 Hold, 1 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Rating Summary:
16 Buy, 11 Hold, 1 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) completed a strong round of financing with a private offering of $110 million in aggregate principal amount of its 3.25 percent Convertible Senior Notes due 2019. Analysts at Jefferies think the deal removes a financing overhang.
Analyst Corey Davis said he had modeled cash needs in 2013 and the financing "provides a clear runway to profitability in ’14". However, Davis isn't expecting a spending spree.
"PCRX may bump up manufacturing capacity investment. We increase the Exparel 'fixed cost' COGS to ~$30M in ’13 (from $27.5M), lowering near-term reported GM. They may also hire a handful more reps, so there may be minor upside to our $48M '13 SG&A, but we'll wait for guidance," said Davis.
Jefferies has a Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX) with a modified price target of $24.00 (from $22.00).
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $19.43 yesterday.
Analyst Corey Davis said he had modeled cash needs in 2013 and the financing "provides a clear runway to profitability in ’14". However, Davis isn't expecting a spending spree.
"PCRX may bump up manufacturing capacity investment. We increase the Exparel 'fixed cost' COGS to ~$30M in ’13 (from $27.5M), lowering near-term reported GM. They may also hire a handful more reps, so there may be minor upside to our $48M '13 SG&A, but we'll wait for guidance," said Davis.
Jefferies has a Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX) with a modified price target of $24.00 (from $22.00).
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $19.43 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AO World Plc. (AO/:LN) PT Raised to GBP1.25 at Jefferies
- Citi Downgrades Malaysia Airports Holdings Bhd (MAHB:MK) (MYPRF) to Neutral
- Jefferies Reiterates Hold Rating on Ocado Group Plc. (OCDO:LN) (OCDGF)
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!